ImmuCell (ICCC) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmuCell is the larger company by market cap ($99.3 million vs $5.1 million), about 19.6 times the size, while Trinity Biotech is growing revenue faster (+8.3% vs +4.3%). ImmuCell converts more of its revenue into profit, with a net margin of -3.8% versus -51.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | TRIB |
|---|---|---|
| Share price | $10.92 | $6.24 |
| Market cap | $99.28M | $5.07M |
| 1-day change | -2.41% | +13.76% |
| YTD return | +77.56% | — |
| 1-year return | +133.33% | — |
| 5-year return | +18.70% | — |
| P/E ratio (TTM) | 57.47 | — |
| EPS (TTM) | $0.19 | $-60.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.64M | $61.55M |
| Revenue growth (YoY) | +4.34% | +8.31% |
| Net income (latest FY) | $-1.04M | $-31.79M |
| Gross margin | 41.40% | 34.83% |
| Operating margin | 5.97% | -34.38% |
| Net margin | -3.76% | -51.64% |
| 52-week high | $12.10 | $52.50 |
| 52-week low | $4.67 | $4.54 |
| Distance from 52-week high | -9.75% | -88.11% |
| Average volume | 13.44K | 13.54K |
| Shares outstanding | 9.09M | 813.13K |
| Employees | 73 | 287 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ImmuCell is about 19.6 times larger than Trinity Biotech by market value ($99.28M vs $5.07M).
- ImmuCell is more profitable, keeping -3.8 cents of every revenue dollar as net income versus -51.6 cents for Trinity Biotech.
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees
ICCC vs TRIB FAQ
Which is bigger, ImmuCell or Trinity Biotech?
ImmuCell (ICCC) is larger, with a market capitalization of $99.28M compared with $5.07M for Trinity Biotech (TRIB).
Are ImmuCell and Trinity Biotech in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.